Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy

Pancreatic adenocarcinoma is a lethal cancer with poor response to chemotherapy and immune checkpoint inhibitors. Recent studies suggest that epigenetic alterations contribute to its aggressive biology and the tumor microenvironment which render it unresponsive to immune checkpoint blockade. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakubo, Kazumichi, Castillo, Carlos Fernandez-del, Liss, Andrew Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596544/
https://www.ncbi.nlm.nih.gov/pubmed/36048239
http://dx.doi.org/10.1007/s00535-022-01915-2
_version_ 1784815895219011584
author Kawakubo, Kazumichi
Castillo, Carlos Fernandez-del
Liss, Andrew Scott
author_facet Kawakubo, Kazumichi
Castillo, Carlos Fernandez-del
Liss, Andrew Scott
author_sort Kawakubo, Kazumichi
collection PubMed
description Pancreatic adenocarcinoma is a lethal cancer with poor response to chemotherapy and immune checkpoint inhibitors. Recent studies suggest that epigenetic alterations contribute to its aggressive biology and the tumor microenvironment which render it unresponsive to immune checkpoint blockade. Here, we review our current understandings of epigenetic dysregulation in pancreatic adenocarcinoma, its effect on the tumor immune microenvironment, and the potential for epigenetic therapy to be combined with immune checkpoint inhibitors.
format Online
Article
Text
id pubmed-9596544
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-95965442022-10-27 Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy Kawakubo, Kazumichi Castillo, Carlos Fernandez-del Liss, Andrew Scott J Gastroenterol Review Pancreatic adenocarcinoma is a lethal cancer with poor response to chemotherapy and immune checkpoint inhibitors. Recent studies suggest that epigenetic alterations contribute to its aggressive biology and the tumor microenvironment which render it unresponsive to immune checkpoint blockade. Here, we review our current understandings of epigenetic dysregulation in pancreatic adenocarcinoma, its effect on the tumor immune microenvironment, and the potential for epigenetic therapy to be combined with immune checkpoint inhibitors. Springer Nature Singapore 2022-09-01 2022 /pmc/articles/PMC9596544/ /pubmed/36048239 http://dx.doi.org/10.1007/s00535-022-01915-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Kawakubo, Kazumichi
Castillo, Carlos Fernandez-del
Liss, Andrew Scott
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
title Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
title_full Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
title_fullStr Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
title_full_unstemmed Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
title_short Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
title_sort epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596544/
https://www.ncbi.nlm.nih.gov/pubmed/36048239
http://dx.doi.org/10.1007/s00535-022-01915-2
work_keys_str_mv AT kawakubokazumichi epigeneticregulationofpancreaticadenocarcinomaintheeraofcancerimmunotherapy
AT castillocarlosfernandezdel epigeneticregulationofpancreaticadenocarcinomaintheeraofcancerimmunotherapy
AT lissandrewscott epigeneticregulationofpancreaticadenocarcinomaintheeraofcancerimmunotherapy

Ejemplares similares